Musculoskeletal Ultrasonographic Evaluation of Lower Limb
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Inflammatory Back Pain in Psoriatic Arthritis Is Significantly More
Haroon et al. Arthritis Research & Therapy (2018) 20:73 https://doi.org/10.1186/s13075-018-1565-4 RESEARCH ARTICLE Open Access Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open- labelled, controlled pilot study Muhammad Haroon1* , Muddassar Ahmad1, Muhammad Nouman Baig2, Olivia Mason3, John Rice2 and Oliver FitzGerald4 Abstract Background: The efficacy of corticosteroids in patients with psoriatic arthritis (PsA) and inflammatory back pain has not been studied to date. In this controlled trial, we aimed to investigate the comparative performance of corticosteroids in patients with active axial-PsA (AxPsA) versus those with active ankylosing spondylitis (AS). Methods: Patients with AxPsA and AS (naïve to biologic therapies), who not only had clinically active disease, but also had bone marrow oedema on magnetic resonance imaging of the sacroiliac joints, were recruited. Clinically active disease was defined as inflammatory back pain (fulfilling Assessment of Spondyloarthritis International Society (ASAS) expert criteria), with spinal pain score (numerical rating scale 0–10) ≥4 and Bath AS Disease Activity Index (BASDAI) score ≥4 despite taking nonsteroidal anti-inflammatory drugs. Moreover, we recruited a control group of patients with non-inflammatory lower back pain. All patients received a single, intra-muscular dose of depot corticosteroid injection (triamcinolone acetonide 80 mg) at baseline. The intra-muscular corticosteroid option was used to overcome any drug compliance issues. Clinical outcome assessments were made at the following time points: baseline, week 2, and week 4. The primary efficacy end point was mean change in Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 2. -
Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort
Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort Mohamed Bedaiwi, Ismail Sari, Arane Thavaneswaran, Renise Ayearst, Nigil Haroon, and Robert D. Inman ABSTRACT. Objective. In this study, we aimed to address the prevalence of fatigue, its associated factors, and the effect of tumor necrosis factor inhibitors (TNFi) on this subgroup of patients in a large axial spondy- loarthritis (axSpA) cohort. Methods. The study included 681 patients [ankylosing spondylitis (AS) and nonradiographic axSpA (nr-axSpA)]. The Fatigue Severity Scale (FSS) and the Bath AS Disease Activity Index question 1 (BASDAI Q1) indices were used for fatigue assessment. Severe fatigue was defined as an FSS ≥ 4 or a BASDAI Q1 ≥ 5. Disease activity, function, and quality of life (QoL) measures were recorded. Patients who had been treated with TNFi were identified, and baseline and followup data were analyzed. Results. Of the cohort, 67.3% had severe fatigue, and the prevalence was similar between AS (67.2%) and nr-axSpA (68.2%). Severely fatigued patients tended to have higher disease activity scores, increased acute-phase proteins, and decreased QoL measures. TNFi therapy was associated with improvement in disease activity, and although this treatment led to significantly decreased fatigue scores, this reduction was not optimal in the majority of patients with 80% continuing to have severe fatigue according to their posttreatment scores. Health Assessment Questionnaire, mean scores of BASDAI Q5 and Q6, and BASDAI enthesitis were independent predictors of fatigue severity. Conclusion. Fatigue is a common symptom in axSpA, and the burden of fatigue among patients with nr-axSpA is similar to that seen in AS. -
Axial Spa Guideline Appendix 6 – Evidence Report
SUPPLEMENTARY APPENDIX 6: Evidence Report 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis Literature Review Members Liron Caplan MD, PhD; Literature Review Lead Marat Turgunbaev MD, MPH Jeff Oristaglio PhD Amit Aakash Shah MD, MPH Nancy Sullivan, BA Walter Maksymowych, MD, FRCPC Core Oversight Team Michael Ward, MD, MPH; Principal Investigator Liron Caplan MD, PhD Atul Deodhar, MD, MRCP ACR Staff Amy Miller; Senior Director, Quality Janet M. Waters, MLS, MLS, BSN, RN, CWCN Regina Parker PICO-specific instructions for the Voting Panel appear in italics below each PICO. Citations in this document appear as: AuthorLastName year [Citation#] where AuthorLastName = last name of the first author for the reference year = year of publication (generally, the print publication) [Citation#] = bibliographic number of the citation in the reference list at the end of this evidence report document Notes GRADE Working Group grades of evidence definitions Very low quality: We are very uncertain about the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. High quality: Further research is very unlikely to change -
Probiotics in Spondyloarthropathy Associated with Ulcerative Colitis: a Pilot Study
European Review for Medical and Pharmacological Sciences 2009; 13: 233-234 Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study Dear Editor, ulcerative colitis (UC) is an inflammatory bowel disease associated with a variety of ex- traintestinal manifestations (EIMs) that may produce greater morbidity than the underlying in- testinal disease and may even be the initial presenting symptoms. An arthritis affecting the spine and/or peripheral joints has been considered the most common EIM of UC. It is charac- terized by the absence of serum rheumatoid factor, the peripheral and axial form occurring in about 10-23% and about 10-15%, respectively1-3. Articular and musculoskeletal manifestations in UC patients are included in the spondyloarthropathies (SpAs) that are a group of seronega- tive autoimmune related disorders with common characteristics including: ankylosing spondyli- tis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease, some forms of juvenile arthritis and acute anterior uveitis4. Evidence coming from many studies in genetically susceptible animal models of colitis sug- gests the crucial role of enteric flora in activating the immune system against bacterial antigens and contemporary against colonic mucosa on the basis of an antigenic cross-reactivity (“antigen mimicry”). The sharing of these colonic antigens by joints, associated with a genetic susceptibility, would lead to an immune attack against these sites5,6. Several studies in animal models of experi- mental arthritis have demonstrated the beneficial effects of probiotics, in particular Lactobacillus species, on articular inflammation7-10. Preliminary results suggest that a probiotic mixture (VSL#3) may be an alternative treatment for arthralgia in patients with inflammatory bowel dis- ease11.